<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107014</url>
  </required_header>
  <id_info>
    <org_study_id>29911</org_study_id>
    <nct_id>NCT02107014</nct_id>
  </id_info>
  <brief_title>Low Dose Naltrexone (LDN) Immune Monitoring</brief_title>
  <acronym>LDN-IM</acronym>
  <official_title>Low Dose Naltrexone (LDN) Immune Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have found that low dose naltrexone (LDN) can substantially reduce pain associated with
      fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The
      purpose of this study is to determine if LDN lowers inflammatory markers in individuals with
      fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women with Fibromyalgia (FM) will be enrolled into a 10-week drug trial. During the
      first two weeks, a baseline phase will be used to collect data on immune function and
      symptoms. LDN will be administered for 8 weeks. Although there is no placebo arm built-in,
      participants will be advised that they may receive a placebo during the trial. Participants
      will provide twice daily symptom reports using an android tablet device and Dooblo SurveyToGo
      survey software. Participants will also provide a blood sample twice every week for the
      duration of the study. Plasma inflammatory markers will be tested using a luminex based
      63-plex inflammatory assay panel.

      The primary aim of the study is to test if 8 weeks of LDN administration is associated with a
      reduction in pro-inflammatory markers in plasma in women with FM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IL-1α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-1β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-1Ra From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-2 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-4 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-5 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-6 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-7 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-8 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-9 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-10 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-12p40 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-12p70 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-13 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-15 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-17A From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-17F From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-18 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-21 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-23 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-31 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-27 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LIF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in G-CSF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GM-CSF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MIP-1α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SDF-1α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IP-10 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Eotaxin From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in RANTES From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MIP-1β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MCP-1 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MCP-3 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MIG From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TRAIL From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CD40L From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TGF-α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TGF-β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IFN-α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IFN-β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IFN-γ From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TNF-α From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TNF-β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PIGF-1 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SCF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HGF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in VEGF-D From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in VEGF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in NGF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EGF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FGF-β From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in M-CSF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in BDNF From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ICAM-1 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in VCAM-1 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ENA-78 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PDGF-BB From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PAI-1 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Leptin From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Resistin From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GROa From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FaSL From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL-22 From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
    <description>Visual analog scale (0-100) anchored at &quot;no pain&quot; at 0 and &quot;worst possible pain&quot; at 100. Improvement in pain would be indicated by a decrease in the score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Overall Fibromyalgia Symptoms From Baseline.</measure>
    <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
    <description>Visual analog scale (0-100) anchored at &quot;no symptoms&quot; at 0 and &quot;worst possible symptoms&quot; at 100. Improvement in overall fibromyalgia symptoms would be indicated by a decrease in the score.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Low Dose Naltrexone (LDN)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Naltrexone</intervention_name>
    <description>Naltrexone 4.5 mg p.o. nocte</description>
    <arm_group_label>Low Dose Naltrexone (LDN)</arm_group_label>
    <other_name>LDN</other_name>
    <other_name>Naltrexone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females age 18-65

          -  Meets criteria for 1990 ACR criteria for fibromyalgia

          -  Able to receive venous blood draw twice a week for 16 weeks

          -  Sufficient symptom variability during baseline report

          -  Patient completes daily report during 2 week baseline period at least 80% completion
             rate.

        Exclusion Criteria:

          -  Opioid use

          -  Significant psychological comorbidity that in the discretion of the investigator
             compromises study integrity

          -  Location prohibits travel to Stanford

          -  Blood or clotting disorder

          -  Rheumatologic or autoimmune disease

          -  Acute infection

          -  Baseline blood ESR &gt;60, CRP greater than 3.0mg/L, positive rheumatoid factor, or
             positive ANA

          -  Use of blood thinning medication

          -  Pregnant or currently planning to become pregnant

          -  Current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory
             medication as part of regular medication regimen.

          -  Known allergy to Naltrexone or Naloxone

          -  Currently participating in another treatment-based research study

          -  Self-reported inability to refrain from alcohol for the duration of the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarred Younger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>December 28, 2016</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jarred W. Younger</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited Feb-April 2014 from a laboratory database of individuals with fibromyalgia who are interested in participating in research.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Naltrexone (LDN)</title>
          <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew before drug: moving interstate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Naltrexone (LDN)</title>
          <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-1α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-1α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" lower_limit="3.52" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.79" upper_limit="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.576</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-1β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-1β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.16" upper_limit="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit=".04" upper_limit="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-1Ra From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-1Ra From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1Ra baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2433.11" lower_limit="2406.25" upper_limit="2500.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1Ra last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2004.48" lower_limit="1846.09" upper_limit="2164.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-2 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-2 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-2 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.21" lower_limit="4.98" upper_limit="105.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.32" lower_limit="4.98" upper_limit="83.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.015</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-4 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-4 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-4 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.70" lower_limit="14.63" upper_limit="100.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.00" lower_limit="13.10" upper_limit="83.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.007</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-5 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-5 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-5 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.33" upper_limit="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" lower_limit="1.24" upper_limit="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.016</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-6 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.22" lower_limit="9.46" upper_limit="27.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" lower_limit="3.64" upper_limit="23.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-7 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-7 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-7 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" lower_limit="9.31" upper_limit="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" lower_limit="8.31" upper_limit="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-8 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-8 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-8 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-9 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-9 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-9 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-9 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-10 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-10 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-10 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="5.26" upper_limit="67.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" lower_limit="6.35" upper_limit="52.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-12p40 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-12p40 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-12p40 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" lower_limit="4.74" upper_limit="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p40 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.43" lower_limit="5.09" upper_limit="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-12p70 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-12p70 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-12p70 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" lower_limit="1.68" upper_limit="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.60" upper_limit="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-13 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-13 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-13 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.16" upper_limit="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.31" upper_limit="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-15 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-15 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-15 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.08" lower_limit="7.07" upper_limit="119.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-15 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.71" lower_limit="7.07" upper_limit="105.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-17A From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-17A From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-17A baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" lower_limit="3.05" upper_limit="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" lower_limit="2.05" upper_limit="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-17F From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-17F From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-17F baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.80" upper_limit="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17F last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.82" upper_limit="10.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-18 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-18 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-18 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.61" lower_limit="3.23" upper_limit="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-18 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" lower_limit="2.99" upper_limit="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-21 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-21 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-21 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.96" lower_limit="13.50" upper_limit="725.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.07" lower_limit="27.30" upper_limit="644.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.478</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-23 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-23 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-23 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-23 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-31 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-31 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-31 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-31 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-27 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-27 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-27 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.51" lower_limit="35.49" upper_limit="156.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-27 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.39" lower_limit="74.66" upper_limit="126.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in LIF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LIF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LIF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" lower_limit="3.98" upper_limit="87.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LIF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="4.19" upper_limit="84.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in G-CSF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in G-CSF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G-CSF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" lower_limit="22.63" upper_limit="152.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.67" lower_limit="23.26" upper_limit="146.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in GM-CSF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GM-CSF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GM-CSF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5779.44" lower_limit="3252.62" upper_limit="26170.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6377.62" lower_limit="2456.04" upper_limit="29829.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MIP-1α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MIP-1α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIP-1α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" lower_limit="2.85" upper_limit="63.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="2.33" upper_limit="56.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in SDF-1α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SDF-1α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SDF-1α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.14" lower_limit="95.03" upper_limit="1886.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDF-1α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.19" lower_limit="98.62" upper_limit="1955.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IP-10 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IP-10 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IP-10 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="4.59" upper_limit="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" lower_limit="4.73" upper_limit="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.558</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Eotaxin From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eotaxin From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>eotaxin baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" lower_limit="19.41" upper_limit="78.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eotaxin last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.95" lower_limit="22.0" upper_limit="80.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in RANTES From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in RANTES From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RANTES baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="49.04" upper_limit="105.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RANTES last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.27" lower_limit="47.15" upper_limit="123.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MIP-1β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MIP-1β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIP-1β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.52" lower_limit="18.91" upper_limit="288.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.08" lower_limit="35.79" upper_limit="272.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.248</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MCP-1 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MCP-1 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCP-1 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.30" lower_limit="15.25" upper_limit="87.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.38" lower_limit="19.60" upper_limit="74.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MCP-3 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MCP-3 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCP-3 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.52" lower_limit="22.67" upper_limit="80.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-3 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.30" lower_limit="17.96" upper_limit="81.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MIG From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MIG From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIG baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.81" lower_limit="28.80" upper_limit="1480.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIG last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.98" lower_limit="27.73" upper_limit="1520.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.962</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TRAIL From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TRAIL From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TRAIL baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" lower_limit="5.41" upper_limit="925.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAIL last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.95" lower_limit="7.42" upper_limit="975.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.402</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CD40L From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD40L From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.97" lower_limit="30.11" upper_limit="316.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.78" lower_limit="19.50" upper_limit="281.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TGF-α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TGF-α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TGF-α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="0.53" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.18" upper_limit="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TGF-β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TGF-β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TGF-β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" lower_limit="7.03" upper_limit="159.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" lower_limit="6.05" upper_limit="141.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IFN-α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IFN-α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" lower_limit="3.19" upper_limit="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="3.57" upper_limit="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IFN-β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IFN-β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.04" lower_limit="14.07" upper_limit="215.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.10" lower_limit="15.81" upper_limit="179.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IFN-γ From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IFN-γ From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-γ baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" lower_limit="5.99" upper_limit="31.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" lower_limit="7.18" upper_limit="25.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TNF-α From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TNF-α From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-α baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.36" lower_limit="90.05" upper_limit="368.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.04" lower_limit="89.75" upper_limit="339.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TNF-β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TNF-β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in PIGF-1 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PIGF-1 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PIGF-1 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.65" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIGF-1 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.98" upper_limit="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.508</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in SCF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SCF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.53" lower_limit="3.05" upper_limit="66.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" lower_limit="2.21" upper_limit="65.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in HGF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HGF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HGF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.27" lower_limit="150.29" upper_limit="1627.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HGF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.33" lower_limit="130.54" upper_limit="1582.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in VEGF-D From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VEGF-D From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VEGF-D baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="0.43" upper_limit="55.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" lower_limit="0.81" upper_limit="56.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.753</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in VEGF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VEGF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VEGF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.95" lower_limit="29.94" upper_limit="710.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.70" lower_limit="33.64" upper_limit="689.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in NGF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NGF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NGF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.24" lower_limit="4.32" upper_limit="150.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NGF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" lower_limit="1.88" upper_limit="139.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in EGF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EGF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" lower_limit="1.77" upper_limit="97.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" lower_limit="0.35" upper_limit="41.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.639</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in FGF-β From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FGF-β From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FGF-β baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF-β last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in M-CSF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in M-CSF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M-CSF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-CSF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in BDNF From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BDNF From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BDNF baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="777.60" lower_limit="478.46" upper_limit="1687.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BDNF last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717.98" lower_limit="399.81" upper_limit="1824.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.945</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ICAM-1 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ICAM-1 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICAM-1 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2670.81" lower_limit="1368.85" upper_limit="4326.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2820.63" lower_limit="1569.72" upper_limit="3802.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in VCAM-1 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VCAM-1 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VCAM-1 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30876.40" lower_limit="28221.23" upper_limit="54690.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VCAM-1 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32156.99" lower_limit="26838.15" upper_limit="70652.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in ENA-78 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ENA-78 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ENA-78 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.64" lower_limit="20.40" upper_limit="226.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ENA-78 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.36" lower_limit="16.32" upper_limit="197.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in PDGF-BB From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PDGF-BB From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PDGF-BB baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.89" lower_limit="129.46" upper_limit="269.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDGF-BB last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.29" lower_limit="122.19" upper_limit="305.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in PAI-1 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PAI-1 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAI-1 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15086.40" lower_limit="13707.57" upper_limit="23919.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAI-1 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15536.99" lower_limit="14295.96" upper_limit="29989.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.610</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Leptin From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leptin From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>leptin baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3991.44" lower_limit="1950.32" upper_limit="8616.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>leptin last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4128.32" lower_limit="1762.54" upper_limit="9120.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.893</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Resistin From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Resistin From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Resistin baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1831.26" lower_limit="1504.34" upper_limit="2771.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistin last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1942.47" lower_limit="1722.55" upper_limit="3009.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in GROa From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GROa From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GROa baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GROa last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in FaSL From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FaSL From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FaSL baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FaSL last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in IL-22 From Baseline.</title>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-22 From Baseline.</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-22 baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.59" lower_limit="99.61" upper_limit="1193.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-22 last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.62" lower_limit="132.15" upper_limit="1012.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.967</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain From Baseline.</title>
        <description>Visual analog scale (0-100) anchored at &quot;no pain&quot; at 0 and &quot;worst possible pain&quot; at 100. Improvement in pain would be indicated by a decrease in the score.</description>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain From Baseline.</title>
          <description>Visual analog scale (0-100) anchored at &quot;no pain&quot; at 0 and &quot;worst possible pain&quot; at 100. Improvement in pain would be indicated by a decrease in the score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.149" spread="4.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.286" spread="4.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Overall Fibromyalgia Symptoms From Baseline.</title>
        <description>Visual analog scale (0-100) anchored at &quot;no symptoms&quot; at 0 and &quot;worst possible symptoms&quot; at 100. Improvement in overall fibromyalgia symptoms would be indicated by a decrease in the score.</description>
        <time_frame>Baseline period (2 weeks) through end of drug phase (8 weeks) [10 weeks total].</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Naltrexone (LDN)</title>
            <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Overall Fibromyalgia Symptoms From Baseline.</title>
          <description>Visual analog scale (0-100) anchored at &quot;no symptoms&quot; at 0 and &quot;worst possible symptoms&quot; at 100. Improvement in overall fibromyalgia symptoms would be indicated by a decrease in the score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall symptoms baseline 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.653" spread="4.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall symptoms last 2-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.506" spread="4.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 week drug administration period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Naltrexone (LDN)</title>
          <description>Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
Low Dose Naltrexone: Naltrexone 4.5 mg p.o. nocte</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No placebo control drug used - participants were only advised that placebo may be used during the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jarred Younger</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>2059755821</phone>
      <email>younger@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

